Contraction (Exercise) Mediated Glucose Uptake as a Therapeutic Target in Type 2 Diabetes

This study has been completed.
Sponsor:
Collaborators:
National Health and Medical Research Council, Australia
Hoffmann-La Roche
Diabetes Australia
Information provided by:
Baker Heart Research Institute
ClinicalTrials.gov Identifier:
NCT00168519
First received: September 14, 2005
Last updated: December 14, 2009
Last verified: December 2009
  Purpose

The purpose of this project is to determine whether glucose metabolism can be improved by administering a substance (nitric oxide donor) normally released by muscles during exercise.


Condition Intervention
Diabetes Mellitus, Type 2
Drug: nitroprusside, pentalong, imdur, AICAR, isoptin

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Pharmacokinetics/Dynamics Study
Intervention Model: Crossover Assignment
Masking: Single Blind (Subject)
Primary Purpose: Treatment
Official Title: Contraction Mediated Glucose Uptake as a Therapeutic Target in Type 2 Diabetes

Resource links provided by NLM:


Further study details as provided by Baker Heart Research Institute:

Primary Outcome Measures:
  • glucose metabolism [ Time Frame: 3 hours ] [ Designated as safety issue: No ]

Estimated Enrollment: 40
Study Start Date: October 2002
Study Completion Date: April 2009
Arms Assigned Interventions
Active Comparator: 1 Drug: nitroprusside, pentalong, imdur, AICAR, isoptin

Sodium Nitroprusside - one 30 minute intravenous infusion

Pentalong - two tablets orally (total 160mg)

Imdur - two tablets orally (total 120mg)


  Show Detailed Description

  Eligibility

Ages Eligible for Study:   18 Years to 65 Years
Genders Eligible for Study:   Male
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

Patients with type 2 diabetes

  • Non-smokers
  • Free of overt coronary disease (stress ECG)
  • Body mass index < 35 kg.m-2
  • Fasting plasma glucose > 7 mmol.L-1 and / or post 75 gm oral glucose load plasma glucose levels of > 11.1 mmol.L-1
  • Unmedicated (diet controlled)

Healthy controls

  • Non-smokers
  • Free of overt coronary disease (ECG)
  • Body mass index < 30 kg.m-2
  • Fasting plasma glucose < 6.1 mmol.L-1
  • Unmedicated
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00168519

Locations
Australia, Victoria
Baker Heart Research Institute
Melbourne, Victoria, Australia, 8008
Sponsors and Collaborators
Baker Heart Research Institute
National Health and Medical Research Council, Australia
Hoffmann-La Roche
Diabetes Australia
Investigators
Principal Investigator: Bronwyn A Kingwell, PhD Baker Heart Research Institute
  More Information

No publications provided

ClinicalTrials.gov Identifier: NCT00168519     History of Changes
Other Study ID Numbers: 51/02
Study First Received: September 14, 2005
Last Updated: December 14, 2009
Health Authority: Australia: Department of Health and Ageing Therapeutic Goods Administration

Keywords provided by Baker Heart Research Institute:
Diabetes Mellitus, Type 2
Blood Glucose
Exercise
Muscle Contraction
Nitric Oxide
Nitrates

Additional relevant MeSH terms:
Diabetes Mellitus
Diabetes Mellitus, Type 2
Glucose Metabolism Disorders
Metabolic Diseases
Endocrine System Diseases
Verapamil
Nitroprusside
Vasodilator Agents
Cardiovascular Agents
Therapeutic Uses
Pharmacologic Actions
Anti-Arrhythmia Agents
Calcium Channel Blockers
Membrane Transport Modulators
Molecular Mechanisms of Pharmacological Action
Nitric Oxide Donors
Antihypertensive Agents

ClinicalTrials.gov processed this record on April 17, 2014